Phase III results of a recent study (TOURMALINE-MM4) show that Ninlaro (ixazomib) can prolong survival when used as maintenance therapy for multiple myeloma patients who are not fit enough to receive a stem cell transplant. Ninlaro is in a class of drugs called proteasome inhibitors.
Revlimid (lenalomide), an immumomodulator, is commonly used in today’s myeloma clinic as maintenance therapy. The results of this study show that Ninlaro as an additional maintenance therapy option may also be helpful.
Study authors reviewed data from four different Ninlaro studies for 706 newly diagnosed myeloma patients where they received induction therapy with once or twice-weekly ixazomib plus one of the following combinations:
Patients were then given only ixazomib as maintenance therapy until disease progression. A total of 121 patients achieved stable disease or better after their initial myeloma treatment:
Once weekly IRD = 25 patients
Twice weekly IRD – 18 patients
Once or twice weekly IMP = 35 patients
Weekly ICD = 43 patients
About 22% of the myeloma patients had a complete response after their initial therapy. A total of 28 patients (23%) improved their response during maintenance. After maintenance therapy, that number grew to 35%. Study authors noted:
“There is increasing evidence for the clinical benefit of long-term, continuous therapy in patients with newly diagnosed multiple myeloma, irrespective of whether they undergo autologous stem cell transplantation.”
Maintenance therapy is typically a lower dose of medication for an extended period of time and for many myeloma patients, it can extend their remissions considerably. We’ll learn more at the upcoming ASH 2019 meeting in Orlando about this convenient and oral option.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.
SIGN UP FOR OUR NEWSLETTER
Get the latest thought leadership on multiple myeloma delivered straight to your inbox.
Many of us, most likely, read as much as we can about CAR-T treatments. Not that there is an abundance of data out yet for the multiple myeloma CAR-T products that are at late development stage. Much of what we find are patient/caregiver testimonials, some with positive results, some not so. Once in a while […]
The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. A small fraction of multiple myeloma patients may already be cured but researchers […]
An antibody drug conjugate is a type of immunotherapy being explored in multiple myeloma. Glaxo-Smith Klein is developing a new antibody drug conjugate in myeloma called Belantamab mafodotin (or “belmaf” for short). These drugs use the immune system to find the right myeloma-specific target and then drop a toxic payload in a targeted way. At […]